Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
The Johnson & Johnson vaccine, which is easier to store and deliver, will help speed up the coronavirus vaccine rollout.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
Moderna’s coronavirus vaccine is 94% effective in preventing symptomatic COVID-19—and it may also reduce asymptomatic infection.
The test is authorized for individuals two years of age or older, including those not showing symptoms.
Pfizer/BioNTech’s coronavirus vaccine is 95% effective for preventing symptomatic illness.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
Bamlanivimab is now authorized for nonhospitalized people at high risk for progressing to severe COVID-19.
Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
The new credit card-size rapid antigen test can return results in 15 minutes.
“The SalivaDirect test...is yet another testing innovation game changer that will reduce the demand for scarce testing resources.”
The immune modulator Pomalyst led to remission in two thirds of people with AIDS-related Kaposi sarcoma.
The single-tablet regimen is now approved for previously treated people with an undetectable viral load.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.